Clinical Trial Update: Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating octreotide to prevent diarrhea in patients receiving irinotecan for metastatic colorectal cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• Sandostatin (Octreotide acetate)

Snippet

Sponsor: Novartis | Conditions: Colorectal Cancer, Diarrhea | Phase 3 | Status: TERMINATED